pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hy
770 Lindaro Street, San Rafael, CA 94901, US HQ
1997 Founded
3,171 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- 770 Lindaro Street, San Rafael, CA 94901, US
- Founded
- 1997
- Employees
- 3,171
- Programs
- 91
- Drugs
- 36
- Patents
- 175
BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)
Phase 2 · mab · Jansky-Bielschowsky Disease
BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1) for Jansky-Bielschowsky Disease is a Phase 2 program (mab) at BioMarin Pharmaceutical Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code 190-203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BioMarin Pharmaceutical Australia Pty Ltd
- Phase
- Phase 2
- Modality
- mab
- Indication
- Jansky-Bielschowsky Disease
- Status
- completed
- Trials
- 1